A Longitudinal Study of Risk Factors for Community-based Home Help Services in Alzheimer's Disease: the Influence of Cholinesterase Inhibitor Therapy

Overview

Journal Clin Interv Aging

Publisher Dove Medical Press

Specialty Geriatrics

Date 2013 May 18

PMID 23682212

Citations 12

Authors

Carina Wattmo

Elisabeth Paulsson

Lennart Minthon

Elisabet Londos

Affiliations

Soon will be listed here.

Abstract

Background: To investigate the long-term effects of cholinesterase inhibitor (ChEI) therapy and the influence of sociodemographic and clinical factors on the use of community-based home help services (HHS) by patients with Alzheimer's disease (AD).

Methods: This 3-year, prospective, multicenter study included 880 AD patients treated with donepezil, rivastigmine, or galantamine in a routine clinical setting. At baseline and every 6 months, the patients were assessed with several rating scales, including the Mini-Mental State Examination, Instrumental Activities of Daily Living (IADL), and Physical Self-Maintenance Scale. Doses of ChEI and amounts of HHS per week were recorded. Cox regression models were used to predict the time to HHS, and multiple linear regression was used to predict the volume of HHS used.

Results: During the study, 332 patients (38%) used HHS. Factors that both postponed HHS use and predicted lower amounts of HHS were higher doses of ChEIs, better IADL ability, and living with family. Men, younger individuals, and those with a slower IADL decline showed a longer time to HHS, whereas female sex, a lower cognitive status, or more medications at baseline predicted fewer hours of HHS.

Conclusions: Higher doses of ChEI might reduce the use of HHS, possibly reducing the costs of community-based care. Female spouses provide more informal care than do male spouses, so the likelihood of using HHS is greater among women with AD. The "silent group" of more cognitively impaired and frail elderly AD patients receives less HHS, which might precipitate institutionalization.

Citing Articles

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease.

Wattmo C, Blennow K, Hansson O BMC Neurol. 2020; 20(1):10.

PMID: 31918679 PMC: 6951013. DOI: 10.1186/s12883-019-1591-0.

Computer-Aided Multi-Target Management of Emergent Alzheimer's Disease.

Kim H, Han H Bioinformation. 2018; 14(4):167-180.

PMID: 29983487 PMC: 6016757. DOI: 10.6026/97320630014167.

Cholinesterase inhibitors do not alter the length of stay in nursing homes among patients with Alzheimer's disease: a prospective, observational study of factors affecting survival time from admission to death.

Wattmo C, Londos E, Minthon L BMC Neurol. 2016; 16(1):156.

PMID: 27581368 PMC: 5007849. DOI: 10.1186/s12883-016-0675-3.

Real-world evaluation of compliance and preference in Alzheimer's disease treatment.

Pai M, Aref H, Bassil N, Kandiah N, Lee J, Srinivasan A Clin Interv Aging. 2015; 10:1779-87.

PMID: 26622172 PMC: 4639476. DOI: 10.2147/CIA.S85319.

Lifetime expectancy and quality-adjusted life-year in Alzheimer's disease with and without cerebrovascular disease: effects of nursing home replacement and donepezil administration--a retrospective analysis in the Tajiri Project.

Meguro K, Akanuma K, Meguro M, Kasai M, Ishii H, Yamaguchi S BMC Neurol. 2015; 15:227.

PMID: 26542372 PMC: 4635582. DOI: 10.1186/s12883-015-0475-1.

References

Hawranik P . The role of cognitive status in the use of inhome services: implications for nursing assessment. Can J Nurs Res. 1998; 30(2):45-65. View

Lopez O, Becker J, Wisniewski S, Saxton J, Kaufer D, DeKosky S . Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2002; 72(3):310-4. PMC: 1737770. DOI: 10.1136/jnnp.72.3.310. View

Doty P, Jackson M, Crown W . The impact of female caregivers' employment status on patterns of formal and informal eldercare. Gerontologist. 1998; 38(3):331-41. DOI: 10.1093/geront/38.3.331. View

Lawton M, Brody E . Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969; 9(3):179-86. View

Birks J . Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006; (1):CD005593. PMC: 9006343. DOI: 10.1002/14651858.CD005593. View

Wattmo C, Wallin A, Londos E, Minthon L . Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment. Alzheimer Dis Assoc Disord. 2010; 25(1):63-72. DOI: 10.1097/WAD.0b013e3181f5dd97. View

Wimo A, Sjolund B, Skoldunger A, Johansson L, Nordberg G, Von Strauss E . Incremental patterns in the amount of informal and formal care among non-demented and demented elderly persons: results from a 3-year follow-up population-based study. Int J Geriatr Psychiatry. 2010; 26(1):56-64. DOI: 10.1002/gps.2488. View

Wenger G, Burholt V, Scott A . Dementia and help with household tasks: a comparison of cases and non-cases. Health Place. 2000; 4(1):33-44. DOI: 10.1016/s1353-8292(97)00024-5. View

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E . Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984; 34(7):939-44. DOI: 10.1212/wnl.34.7.939. View

10.

Kadushin G . Home health care utilization: a review of the research for social work. Health Soc Work. 2004; 29(3):219-44. DOI: 10.1093/hsw/29.3.219. View

11.

Small G, Kaufer D, Mendiondo M, Quarg P, Spiegel R . Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years. Int J Clin Pract. 2005; 59(4):473-7. DOI: 10.1111/j.1368-5031.2005.00524.x. View

12.

Ott A, Breteler M, Van Harskamp F, Claus J, van der Cammen T, Grobbee D . Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study. BMJ. 1995; 310(6985):970-3. PMC: 2549358. DOI: 10.1136/bmj.310.6985.970. View

13.

Bass D, Looman W, Ehrlich P . Predicting the volume of health and social services: integrating cognitive impairment into the modified Andersen framework. Gerontologist. 1992; 32(1):33-43. DOI: 10.1093/geront/32.1.33. View

14.

Geldmacher D, Provenzano G, McRae T, Mastey V, Ieni J . Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc. 2003; 51(7):937-44. DOI: 10.1046/j.1365-2389.2003.51306.x. View

15.

Jonsson L, Eriksdotter Jonhagen M, Kilander L, Soininen H, Hallikainen M, Waldemar G . Determinants of costs of care for patients with Alzheimer's disease. Int J Geriatr Psychiatry. 2006; 21(5):449-59. DOI: 10.1002/gps.1489. View

16.

Feldman H, Van Baelen B, Kavanagh S, Torfs K . Cognition, function, and caregiving time patterns in patients with mild-to-moderate Alzheimer disease: a 12-month analysis. Alzheimer Dis Assoc Disord. 2005; 19(1):29-36. DOI: 10.1097/01.wad.0000157065.43282.bc. View

17.

Folstein M, Folstein S, McHugh P . "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-98. DOI: 10.1016/0022-3956(75)90026-6. View

18.

Winblad B, Wimo A, Engedal K, Soininen H, Verhey F, Waldemar G . 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dement Geriatr Cogn Disord. 2006; 21(5-6):353-63. DOI: 10.1159/000091790. View

19.

Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E . Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet. 2004; 363(9427):2105-15. DOI: 10.1016/S0140-6736(04)16499-4. View

20.

Lagergren M . The systems of care for frail elderly persons: the case of Sweden. Aging Clin Exp Res. 2002; 14(4):252-7. DOI: 10.1007/BF03324447. View